Skip to main content
Top
Published in: Discover Oncology 4/2015

01-08-2015 | Original Paper

Influence of Cancer-Associated Endometrial Stromal Cells on Hormone-Driven Endometrial Tumor Growth

Authors: M. J. Pineda, Z. Lu, D. Cao, J. J. Kim

Published in: Discover Oncology | Issue 4/2015

Login to get access

Abstract

Cancer-associated fibroblasts have been shown to inhibit or stimulate tumor growth depending on stage, grade, and tumor type. It remains unclear, however, the effect of endometrial-cancer-associated fibroblasts on hormone-driven responses in endometrial cancer. In this study, we investigated the effect of normal and cancer-associated stromal cells from patients with and without endometrial cancer on endometrial tumor growth in response to estradiol (E2) and progesterone (P4). Compared to benign endometrial stromal cells, the low-grade and high-grade cancer-associated stromal cells exhibited a blunted hormone response for proliferation as well as IGFBP1 secretion. Additional analysis of the influence of stromal cells on hormone-driven tumor growth was done by mixing stromal cells from benign, low-grade, or high-grade tumors, with Ishikawa cells for subcutaneous tumor formation. The presence of both benign and high-grade cancer-associated stromal cells increased estradiol-driven xenografted tumor growth compared to Ishikawa cells alone. Low-grade cancer-associated stromal cells did not significantly influence hormone-regulated tumor growth. Addition of P4 attenuated tumor growth in Ishikawa + benign or high-grade stromal cells, but not in Ishikawa cells alone or with low-grade stromal cells. Using an angiogenesis focused real-time array TGFA, TGFB2 and TGFBR1 and VEGFC were identified as potential candidates for hormone-influenced growth regulation of tumors in the presence of benign and high-grade stromal cells. In summary, endometrial-cancer-associated cells responded differently to in vitro hormone treatment compared to benign endometrial stromal cells. Additionally, presence of stromal cells differentially influenced hormone-driven xenograft growth in vivo depending on the disease status of the stromal cells.
Appendix
Available only for authorised users
Literature
3.
go back to reference American Cancer Society (2014) Cancer Facts Fig American Cancer Society (2014) Cancer Facts Fig
4.
go back to reference Anzai Y, Gong Y, Holinka CF, Murphy LJ, Murphy LC, Kuramoto H, Gurpide E (1992) Effects of transforming growth factors and regulation of their mRNA levels in two human endometrial adenocarcinoma cell lines. J Steroid Biochem Mol Biol 42(5):449–455PubMedCrossRef Anzai Y, Gong Y, Holinka CF, Murphy LJ, Murphy LC, Kuramoto H, Gurpide E (1992) Effects of transforming growth factors and regulation of their mRNA levels in two human endometrial adenocarcinoma cell lines. J Steroid Biochem Mol Biol 42(5):449–455PubMedCrossRef
5.
go back to reference Arnold JT, Kaufman DG, Seppala M, Lessey BA (2001) Endometrial stromal cells regulate epithelial cell growth in vitro: a new co-culture model. Hum Reprod 16(5):836–845PubMedCrossRef Arnold JT, Kaufman DG, Seppala M, Lessey BA (2001) Endometrial stromal cells regulate epithelial cell growth in vitro: a new co-culture model. Hum Reprod 16(5):836–845PubMedCrossRef
6.
go back to reference Arnold JT, Lessey BA, Seppala M, Kaufman DG (2002) Effect of normal endometrial stroma on growth and differentiation in Ishikawa endometrial adenocarcinoma cells. Cancer Res 62(1):79–88PubMed Arnold JT, Lessey BA, Seppala M, Kaufman DG (2002) Effect of normal endometrial stroma on growth and differentiation in Ishikawa endometrial adenocarcinoma cells. Cancer Res 62(1):79–88PubMed
7.
go back to reference Bausero P, Cavaille F, Meduri G, Freitas S, Perrot-Applanat M (1998) Paracrine action of vascular endothelial growth factor in the human endometrium: production and target sites, and hormonal regulation. Angiogenesis 2(2):167–182PubMedCrossRef Bausero P, Cavaille F, Meduri G, Freitas S, Perrot-Applanat M (1998) Paracrine action of vascular endothelial growth factor in the human endometrium: production and target sites, and hormonal regulation. Angiogenesis 2(2):167–182PubMedCrossRef
9.
go back to reference Chegini N, Zhao Y, Williams RS, Flanders KC (1994) Human uterine tissue throughout the menstrual cycle expresses transforming growth factor-beta 1 (TGF beta 1), TGF beta 2, TGF beta 3, and TGF beta type II receptor messenger ribonucleic acid and protein and contains [125I]TGF beta 1-binding sites. Endocrinology 135(1):439–449. doi:10.1210/endo.135.1.8013382 PubMed Chegini N, Zhao Y, Williams RS, Flanders KC (1994) Human uterine tissue throughout the menstrual cycle expresses transforming growth factor-beta 1 (TGF beta 1), TGF beta 2, TGF beta 3, and TGF beta type II receptor messenger ribonucleic acid and protein and contains [125I]TGF beta 1-binding sites. Endocrinology 135(1):439–449. doi:10.​1210/​endo.​135.​1.​8013382 PubMed
10.
go back to reference Cunha GR, Cooke PS, Kurita T (2004) Role of stromal-epithelial interactions in hormonal responses. Arch Histol Cytol 67(5):417–434PubMedCrossRef Cunha GR, Cooke PS, Kurita T (2004) Role of stromal-epithelial interactions in hormonal responses. Arch Histol Cytol 67(5):417–434PubMedCrossRef
14.
go back to reference Felix AS, Weissfeld J, Edwards R, Linkov F (2010) Future directions in the field of endometrial cancer research: the need to investigate the tumor microenvironment. Eur J Gynaecol Oncol 31(2):139–144PubMedCentralPubMed Felix AS, Weissfeld J, Edwards R, Linkov F (2010) Future directions in the field of endometrial cancer research: the need to investigate the tumor microenvironment. Eur J Gynaecol Oncol 31(2):139–144PubMedCentralPubMed
16.
go back to reference Girling JE, Rogers PA (2009) Regulation of endometrial vascular remodelling: role of the vascular endothelial growth factor family and the angiopoietin-TIE signalling system. Reproduction 138(6):883–893. doi:10.1530/REP-09-0147 PubMedCrossRef Girling JE, Rogers PA (2009) Regulation of endometrial vascular remodelling: role of the vascular endothelial growth factor family and the angiopoietin-TIE signalling system. Reproduction 138(6):883–893. doi:10.​1530/​REP-09-0147 PubMedCrossRef
17.
go back to reference Gold LI, Saxena B, Mittal KR, Marmor M, Goswami S, Nactigal L, Korc M, Demopoulos RI (1994) Increased expression of transforming growth factor beta isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: evidence for paracrine and autocrine action. Cancer Res 54(9):2347–2358PubMed Gold LI, Saxena B, Mittal KR, Marmor M, Goswami S, Nactigal L, Korc M, Demopoulos RI (1994) Increased expression of transforming growth factor beta isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: evidence for paracrine and autocrine action. Cancer Res 54(9):2347–2358PubMed
19.
go back to reference Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y et al (2010) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9(7):1956–1967. doi:10.1158/1535-7163.MCT-09-1012 PubMedCrossRef Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y et al (2010) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9(7):1956–1967. doi:10.​1158/​1535-7163.​MCT-09-1012 PubMedCrossRef
22.
go back to reference Kurita T, Medina R, Schabel AB, Young P, Gama P, Parekh TV, Brody J et al (2005) The activation function-1 domain of estrogen receptor alpha in uterine stromal cells is required for mouse but not human uterine epithelial response to estrogen. Differentiation 73(6):313–322. doi:10.1111/j.1432-0436.2005.00033.x PubMedCrossRef Kurita T, Medina R, Schabel AB, Young P, Gama P, Parekh TV, Brody J et al (2005) The activation function-1 domain of estrogen receptor alpha in uterine stromal cells is required for mouse but not human uterine epithelial response to estrogen. Differentiation 73(6):313–322. doi:10.​1111/​j.​1432-0436.​2005.​00033.​x PubMedCrossRef
23.
go back to reference Kurita T, Wang YZ, Donjacour AA, Zhao C, Lydon JP, O’Malley BW, Isaacs JT, Dahiya R, Cunha GR (2001) Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ 8(2):192–200. doi:10.1038/sj.cdd.4400797 PubMedCrossRef Kurita T, Wang YZ, Donjacour AA, Zhao C, Lydon JP, O’Malley BW, Isaacs JT, Dahiya R, Cunha GR (2001) Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ 8(2):192–200. doi:10.​1038/​sj.​cdd.​4400797 PubMedCrossRef
28.
go back to reference Massague J, Blain SW, Lo RS (2000) TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103(2):295–309PubMedCrossRef Massague J, Blain SW, Lo RS (2000) TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103(2):295–309PubMedCrossRef
29.
go back to reference Moller B, Lindblom B, Olovsson M (2002) Expression of the vascular endothelial growth factors B and C and their receptors in human endometrium during the menstrual cycle. Acta Obstet Gynecol Scand 81(9):817–824PubMedCrossRef Moller B, Lindblom B, Olovsson M (2002) Expression of the vascular endothelial growth factors B and C and their receptors in human endometrium during the menstrual cycle. Acta Obstet Gynecol Scand 81(9):817–824PubMedCrossRef
30.
go back to reference Murphy LJ, Gong Y, Murphy LC (1992) Regulation of transforming growth factor gene expression in human endometrial adenocarcinoma cells. J Steroid Biochem Mol Biol 41(3–8):309–314PubMedCrossRef Murphy LJ, Gong Y, Murphy LC (1992) Regulation of transforming growth factor gene expression in human endometrial adenocarcinoma cells. J Steroid Biochem Mol Biol 41(3–8):309–314PubMedCrossRef
31.
32.
go back to reference Nishida M, Kasahara K, Oki A, Satoh T, Arai Y, Kubo T (1996) Establishment of eighteen clones of Ishikawa cells. Hum Cell 9(2):109–116PubMed Nishida M, Kasahara K, Oki A, Satoh T, Arai Y, Kubo T (1996) Establishment of eighteen clones of Ishikawa cells. Hum Cell 9(2):109–116PubMed
33.
go back to reference Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR (1999) Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59(19):5002–5011PubMed Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR (1999) Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59(19):5002–5011PubMed
35.
go back to reference Piver MS, Barlow JJ, Lurain JR, Blumenson LE (1980) Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma. Cancer 45(2):268–272PubMedCrossRef Piver MS, Barlow JJ, Lurain JR, Blumenson LE (1980) Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma. Cancer 45(2):268–272PubMedCrossRef
36.
go back to reference Podratz KC, O’Brien PC, Malkasian GD Jr, Decker DG, Jefferies JA, Edmonson JH (1985) Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol 66(1):106–110PubMed Podratz KC, O’Brien PC, Malkasian GD Jr, Decker DG, Jefferies JA, Edmonson JH (1985) Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol 66(1):106–110PubMed
38.
go back to reference Quinn MA, Cauchi M, Fortune D (1985) Endometrial carcinoma: steroid receptors and response to medroxyprogesterone acetate. Gynecol Oncol 21(3):314–319PubMedCrossRef Quinn MA, Cauchi M, Fortune D (1985) Endometrial carcinoma: steroid receptors and response to medroxyprogesterone acetate. Gynecol Oncol 21(3):314–319PubMedCrossRef
39.
go back to reference Ripley D, Tang XM, Ma C, Chegini N (2001) The expression and action of granulocyte macrophage-colony stimulating factor and its interaction with TGF-beta in endometrial carcinoma. Gynecol Oncol 81(2):301–309. doi:10.1006/gyno.2001.6161 PubMedCrossRef Ripley D, Tang XM, Ma C, Chegini N (2001) The expression and action of granulocyte macrophage-colony stimulating factor and its interaction with TGF-beta in endometrial carcinoma. Gynecol Oncol 81(2):301–309. doi:10.​1006/​gyno.​2001.​6161 PubMedCrossRef
44.
45.
go back to reference Xu H, Zhang T, Man GC, May KE, Becker CM, Davis TN, Kung AL et al (2013) Vascular endothelial growth factor C is increased in endometrium and promotes endothelial functions, vascular permeability and angiogenesis and growth of endometriosis. Angiogenesis 16(3):541–551. doi:10.1007/s10456-013-9333-1 PubMedCrossRef Xu H, Zhang T, Man GC, May KE, Becker CM, Davis TN, Kung AL et al (2013) Vascular endothelial growth factor C is increased in endometrium and promotes endothelial functions, vascular permeability and angiogenesis and growth of endometriosis. Angiogenesis 16(3):541–551. doi:10.​1007/​s10456-013-9333-1 PubMedCrossRef
Metadata
Title
Influence of Cancer-Associated Endometrial Stromal Cells on Hormone-Driven Endometrial Tumor Growth
Authors
M. J. Pineda
Z. Lu
D. Cao
J. J. Kim
Publication date
01-08-2015
Publisher
Springer US
Published in
Discover Oncology / Issue 4/2015
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-015-0223-4

Other articles of this Issue 4/2015

Discover Oncology 4/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.